GoogleNews-Aggregator

Despite a promising pipeline that includes treatments for Huntington's disease and other conditions, the financial overview reveals significant ...Read more

uniQure N.V. (QURE) plans to begin screening patients by the end of 2026 for an approximately 200-patient confirmatory trial in Huntington's disease.Read more

Preclinical Huntington's disease studies showed candidate compounds reduced mutant huntingtin while preserving normal huntingtin; candidate ...Read more

The company is advancing preclinical characterization of several candidate molecules for its Huntington's disease program. Original SEC Filing ...Read more

... Huntington's disease, cystic fibrosis, Tay-Sachs, and hereditary cancers. By extracting stem cells from the embryos, the researchers can test ...Read more

Related Articles. Huntington's disease treated for the first time using gene therapy · Gene therapy that led to boy's death had limited efficacy.Read more

... disorders. Its commercial portfolio includes therapies for tardive dyskinesia, Huntington's disease chorea, classic congenital adrenal hyperplasia ...Read more

... diseases, including Huntington's disease and multiple sclerosis. Through its affiliated companies, MMJ BioPharma Cultivation, Inc. and MMJ ...Read more

... disease-modifying therapy for Huntington's disease, addressing a critical unmet need for families. Management attributes the strength of the ...Read more

... Disorder Society meeting in Seoul and the European Huntington's Disease Network meeting in Krakow. These specialists describe TSC as the endpoint ...Read more

Huntington's disease (HD): Design continues to advance preclinical characterization of several candidate molecules for its Huntington's disease ...Read more

... Huntington's Disease · Clinical. SEPTEMBER 8, 2026. Online First ...Read more

DT-168 Phase 2 trial in Fuchs endothelial corneal dystrophy continues, with data expected in 2027. Minor pointHuntington's disease program continues ...Read more

uniQure (NASDAQ:QURE) said the FDA has accepted its Biologics License Application for AMT-130, an investigational treatment for Huntington's disease, ...Read more

... Huntington's disease expertise and ... Disorder Society meeting in Seoul and the European Huntington's Disease Network meeting in Krakow.Read more